Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting of ibrutinib resistance-driving pathways by miR-28 in ABC-DLBCL

  • Álvarez-Corrales, Emigdio
  • Moreno-Palomares, Rocío
  • Gómez-Escolar, Carmen
  • Martínez, Mario
  • Moral-Pérez, Udane
  • Laguna-Herrero, María
  • Fuertes, Teresa
  • Estrada, Belén S.
  • Mur, Sonia
  • Bonis, Adriana de
  • Leiva, Magdalena
  • Martínez-Martín, Nuria
  • Somoza, Álvaro
  • Ramiro, Almudena R.
  • Yébenes, Virginia G. de
The RNA-seq datasets generated during the current study are available in the ArrayExpress Functional Genomics Data repository (accession number: E-MTAB-16241)., Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma. Although many patients respond well to R-CHOP immunochemotherapy, those with the activated B-cell (ABC) subtype are often refractory or relapse. Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib have improved outcomes, but acquired resistance limits their long-term efficacy. Here, we modeled the development of ibrutinib resistance in ABC-DLBCL and investigated whether the BCR-signaling regulator microRNA-28 (miR-28) can block this process. Using flow cytometry-based competition assays, multicolor clonal barcoding, transcriptomic profiling, and xenograft models, we found that miR-28 expression impairs the emergence of ibrutinib-resistant ABC-DLBCL cells. Mechanistically, miR-28 interferes with the clonal selection process triggered by ibrutinib treatment and rewires transcriptional programs by downregulating mitochondrial and mTOR signaling pathways critical for resistance development. Furthermore, the miR-28-repressed gene signature associated with ibrutinib resistance correlates with improved survival in ibrutinib-treated patients from the PHOENIX trial cohort with the MCD genetic subtype, which is associated with ABC-DLBCL. Finally, the targeted therapeutic delivery of miR-28 via aptamer-guided nanoparticles suppresses ibrutinib-resistant tumor growth in vivo. These findings identify miR-28 as an effective inhibitor of ibrutinib resistance, underscoring its translational potential as an adjunct strategy in ABC-DLBCL therapy., We thank Janssen and the European Genome-phenome Archive for providing access to data from the PHOENIX trial, the members of the B cell biology lab, Balbino Alarcón, José Luis Marina, and María Jesús García de Yébenes for helpful discussions, and Arantzazu Alfranca for providing the LeGO vectors. E.A.C. and R.M.P were supported by PhD fellowships from the Comunidad de Madrid (PIPF-2022/SAL-GL-24469 and PIPF-2023/SAL-GL-29484 respectively), A.R.R. by CNIC funding and V.G.Y. by the Universidad Complutense de Madrid. B.S.E. is supported by a FPI contract from the Spanish Ministry of Science (PRE2022-102696). This work was funded by Spanish Ministerio de Ciencia e Innovación grants PID2019-107551RB-I00/AEI/10.13039/501100011033 and PID2022-137014OB-I00/AEI/10.13039/501100011033/ FEDER, UE to V.G.Y and PID2023-146982OB-I00, CEX2020-001039-S and PID2024-159895OB-100 to A.S, IMDEA Nanociencia and M.L, respectively. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). N.M.M. lab is supported by the grants CNS2022-135636, PID2021-126298OB-I00, PID2024-162320OB-I00 (founded by MCIU/AEI/10.13039/501100011033/FEDER, UE) and HR22-00447 (founded by La Caixa)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001039-S), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2020-001041-S), Peer reviewed